Follow-up do doente oncológico pulmonar. O Papel do Pneumologista Oncológico

Cunha, João

doi:10.1016/S0873-2159(15)31022-9

Article information

Download PDF

Statistics

Full text is only aviable in PDF

REFERÉNCIAS BIBLIOGRÁFICAS

[1.]

ASCO 32° Annual Meeting 1996.- Educational book. Strategies for follow-up of patients with comun malignancies.

[2.]

W. Shields Thomas.

Postoperative Lung Cancer Surveillance.

Chest, 111 (Jan, 1997), pp. 11-12

Medline

[3.]

A. Clemente Hiebert.

The “Cured” Lung Cancer Patient: Is Follow-up by the Surgeon Worthwhile?.

Ann Thorac Surg, 60 (1995), pp. 1557-1558

http://dx.doi.org/10.1016/0003-4975(95)00892-6 | Medline

[4.]

K.S. Virgo.

Communication 1752.

ASCO, (1997),

[5.]

C. Peter Pairolero, et al.

Postsurgical Stage I Bronchogenic Carcinoma: Morbid Implications of Recurrent Disease.

Ann thorac Surg, 38 (1984), pp. 331-336

Medline

[6.]

P. Thomas.

Cancer Recurrence after Recection: TI NO nsclc: LCSG.

Ann Thorac Surg, 49 (1990), pp. 242-246

Medline

[7.]

E.F. Smit, et al.

New Prognostic factors in resectable nsclc.

Thorac, 51 (1996), pp. 638-646

[8.]

W. Thomas Shield, et al.

Long-term survivors after resection of lung cancer.

J Thorac and Cardiovasc Surg, 76 (1978), pp. 439-445

[9.]

Perez, et al.

Utility of Screening Procedures for Detecting Recurrence of Disease after Complete response in Patients With sclc.

Cancer, 80 (1997), pp. 676-680

Medline

[10.]

Walsh, et al.

Is follow-up of Lung Cancer Patients after Resection Medicaly Indicated and Cost-Effective?.

Ann Thorac Surg, 60 (1995), pp. 1563-1572

http://dx.doi.org/10.1016/0003-4975(95)00893-4 | Medline

[11.]

Naunhelm, et al.

Clinical Surveillance Testing After Lung Cancer Operations.

Ann Thorac Surg, 60 (1995), pp. 1512-1516

[12.]

Virgo, et al.

Cost of patient follow-up after potencially curative lung cancer treatment.

J Thorac Cardiovasc Surg, 112 (1996), pp. 356-363

http://dx.doi.org/10.1016/S0022-5223(96)70262-3 | Medline

[13.]

Edelman.

The utility of follow-up testing after curative cancer therapy.

J Gen Intern Med, 12 (1997), pp. 318-331

Medline

[14.]

N. Johnso, et al.

How Tumor Stage Affects Surgeons Surveillance strategies after lung cancer surgery.

Chest, 111 (1997), pp. 99-102

Medline

[15.]

A. Paul Thomas (Lcsd).

Malignat Disease appearing late after operation for TI NO nsclc.

J Thorac Cardiovasc Surg, 106 (1993), pp. 1053-1058

Medline

[16.]

J.M. Kurie, et al.

Auto fluorescense bronchoscopy in detection of brochial metaplasia and displasia in chronic smokers.

ASCO, (1997),

[17.]

Pinson P., et al.

Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of sclc.

Respiration, 64 (1997), pp. 102-107

Medline

[18.]

Kwiatkowski, et al.

Prognostic factor analysis of 250 stage 1 NSCLC patients.

ASCO, (1997),

[19.]

Viñolas, et al.

Tumor markers (CEA, SCC, CYFRA, CA 125. NSE) in response monitoring and prognosis of NSCLC.

ASCO, (1997),

[20.]

Bram, et al.

CYFRA 21-1 as a Biologic marker of NSCLC.

Chest, 108 (1995), pp. 163-169

Medline

[21.]

A. Tatsuy, et al.

Analysis of early Postoperative Serum CEA Time-Course as a Prognostic Tool for Bronchogenic Carcinoma.

Cancer, 79 (1997), pp. 1533-1540

Medline

[22.]

R.J. Slebos, et al.

K RAS oncogene activation as a Prognostic marker in adenocarcinoma of the lung.

NEJM, 323 (1990), pp. 561-565

http://dx.doi.org/10.1056/NEJM199008303230902 | Medline

[23.]

D.H. Harpole, et al.

Prognostic model of Recurrence and death in stage 1 NSCLC.

Cancer Research, 55 (1995), pp. 51-56

Medline

[24.]

R. Sotto-Mayor, et al.

Oncologia Pneumologica.

Permanyer Portugal, (1993), pp. 5-48

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter